Regeneron's Expense Growth Weighs on Operating Income
07 May 2019 - 9:13PM
Dow Jones News
By Allison Prang
Earnings at Regeneron Pharmaceuticals Inc. (REGN) declined in
the first quarter as expenses grew by 30%, climbing faster than
revenue.
Regeneron reported $461.1 million in profit, which was down 3.5%
from the comparable quarter a year prior. Earnings were $3.99 a
share, down from $4.16 a share.
The company's adjusted earnings were $4.45 a share, down from
$4.67 a share. Analysts polled by Refinitiv were expecting $5.46 a
share.
Revenue rose 13% to $1.71 billion. Analysts were expecting $1.76
billion. Expenses rose 30%.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
May 07, 2019 06:58 ET (10:58 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024